News & Updates

The use of real-time, computer-aided detection of colonic neoplasia leads to modest increases in adenoma detection rate and adenomas detected per colonoscopy in average-detector community endoscopists, as shown in the results of a pragmatic randomized controlled trial.

Dr Aminudin Rahman Mohd Mydin, a consultant clinical oncologist, talks about the role of artificial intelligence (AI) in oncology and the advent of auto-contouring via the application of AI in radiotherapy.

New drug applications approved by US FDA as of 16-29 February 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Patients with inflammatory bowel disease (IBD) appear to have a moderately elevated risk of pancreatic cancer, according to a meta-analysis.

Medication-related osteonecrosis of the jaw (MRONJ), a major side effect of using bone-modifying agents (BMA) for cancer or osteoporosis, normally manifests intraorally. However, some patients may have an extraoral manifestation of erythematous swelling or fistulas localized to the jaw area, according to a recent study.

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.